They revealed that erinacine A and S reduced amyloid plaque formation and enhanced hippocampal neurogenesis in a murine model of APP/PS1 Alzheimer’s disease (AD) by suppressing neuroinflammation and upregulating the expression of insulin-degrading enzymes, highlighting their therapeutic potential in AD. This evidence concerns the gene APP and Alzheimer disease.